Romosozumab Treatment in Postmenopausal Women with Osteoporosis

Osteoporosis can lead to fragility fractures, which result in clinical burden and increased mortality. Even after a fracture, fewer than 25% of patients receive pharmacologic treatment for osteoporosis.3-5 After the discovery that sclerostin deficiency causes rare genetic conditions that are characterized by high bone mass and resistance to fracture,6,7 sclerostin became a therapeutic target for the treatment of osteoporosis. Sclerostin, a negative regulator of bone formation that is secreted by osteocytes,8 inhibits Wnt signaling, down-regulating this stimulus for osteoblast development and function. Romosozumab (Amgen and UCB Pharma) is a monoclonal antibody that binds and inhibits sclerostin, with a dual effect of increasing bone formation and decreasing bone resorption….